Open Access Open Access  Restricted Access Subscription Access

An Indispensable Parameters of Ethosuximide Include Objectives, Indications, Mechanism of Action, Pharmaco Kinetics, Administration, Adverse Effects, Drug-Drug Interactions, Contra-Indications, Toxicity and Healthcare Team Outcomes

Tsappidi Winnie Diana, Revath Kumar Nakka, Moni Theresa Tsappidi, Muralinath E., Srinivas G., Guruprasad M., Ramanjaneyulu D.V.

Abstract


In order to treat absence epilepsy, ethosuximide, a central nervous system drug, is useful. This instructional session gives medical professionals the knowledge they need to provide individualized and focused care. This activity organizes crucial information for the efficient use of ethosuximide, particularly in clinical settings, by outlining its indications, effects, and contraindications. Ethosuximide's mode of action, adverse event profile, dosage recommendations, monitoring needs, and pertinent interactions are all carefully examined. Examining this pharmacological data aids medical practitioners in creating individualized treatment programs that satisfy the needs of each patient, maximizing therapeutic results while reducing the possibility of side effects. Increasing healthcare providers' ability to make informed decisions, particularly while administering ethosuximide, is the main topic of debate. Additionally, this activity emphasizes how important the interprofessional healthcare team is to the successful management of ethosuximide therapy.

 


Full Text:

PDF

References


Flatters, S. J., & Bennett, G. J. (2004). Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain, 109(1–2), 150–161. https://doi.org/10.1016/j.pain.2004.01.021

Dogrul, A., Gardell, L. R., Ossipov, M. H., Tulunay, F. C., Lai, J., & Porreca, F. (2003). Reversal of experimental neuropathic pain by T-type calcium channel blockers. Pain, 105(1–2), 159–168. https://doi.org/10.1016/S0304-3959(03)00232-1

Hamidi, G. A., Ramezani, M. H., Arani, M. N., Talaei, S. A., Mesdaghinia, A., & Banafshe, H. R. (2012). Ethosuximide reduces allodynia and hyperalgesia and potentiates morphine effects in the chronic constriction injury model of neuropathic pain. European Journal of Pharmacology, 674(2–3), 260–264. https://doi.org/10.1016/j.ejphar.2011.11.031

Weinstein, A. W., & Allen, R. J. (1966). Ethosuximide treatment of petit mal seizures: A study of 87 pediatric patients. American Journal of Diseases of Children, 111(1), 63–67. https://doi.org/10.1001/archpedi.1966.02090040065008

Browne, T. R., Dreifuss, F. E., Dyken, P. R., Goode, D. J., Penry, J. K., Porter, R. J., White, B. G., & White, P. T. (1975). Ethosuximide in the treatment of absence (petit mal) seizures. Neurology, 25(6), 515–524. https://doi.org/10.1212/wnl.25.6.515

Glauser, T. A., Cnaan, A., Shinnar, S., Hirtz, D. G., Dlugos, D., Masur, D., Clark, P. O., Capparelli, E. V., Adamson, P. C., & Childhood Absence Epilepsy Study Group. (2010). Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. The New England Journal of Medicine, 362(9), 790–799. https://doi.org/10.1056/NEJMoa0902335

Glauser, T. A., Cnaan, A., Shinnar, S., Hirtz, D. G., Dlugos, D., Masur, D., Clark, P. O., Adamson, P. C., & Childhood Absence Epilepsy Study Team. (2013). Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: Initial monotherapy outcomes at 12 months. Epilepsia, 54(1), 141–155. https://doi.org/10.1111/j.1528-1167.2012.03666.x

Brigo, F., & Igwe, S. C. (2017). Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database of Systematic Reviews, 2017(2), CD003032. https://doi.org/10.1002/14651858.CD003032.pub3

Le Roux, M., Benallegue, N., Gueden, S., Rupin-Mas, M., & Van Bogaert, P. (2024). Care of pharmaco-resistant absence seizures in childhood. Revue Neurologique, 180(4), 251–255. https://doi.org/10.1016/j.neurol.2024.01.012

Conecker, G., Xia, M. Y., Hecker, J., Achkar, C., Cukiert, C., Devries, S., Donner, E., Fitzgerald, M. P., Gardella, E., Hammer, M., Hegde, A., Hu, C., Kato, M., Luo, T., Schreiber, J. M., Wang, Y., Kooistra, T., Oudin, M., Waldrop, K., ... Perry, M. S. (2024). Global modified Delphi consensus on diagnosis, phenotypes, and treatment of SCN8A-related epilepsy and/or neurodevelopmental disorders. Epilepsia, 65(8), 2322–2338. https://doi.org/10.1111/epi.17956

Smith, K. M., Wirrell, E. C., Andrade, D. M., Choi, H., Trenité, D. K., Jones, H., Knupp, K. G., Mugar, J., Nordli, D. R., Riva, A., Stern, J. M., Striano, P., Thiele, E. A., Zawar, I. (2023). Management of epilepsy with eyelid myoclonia: Results of an international expert consensus panel. Epilepsia, 64(9), 2342–2350. https://doi.org/10.1111/epi.17848

Goldensohn, E. S., Hardie, J., & Borea, E. D. (1962). Ethosuximide in the treatment of epilepsy. JAMA, 180, 840–842. https://doi.org/10.1001/jama.1962.03050090018005

Sills, G. J., & Rogawski, M. A. (2020). Mechanisms of action of currently used antiseizure drugs. Neuropharmacology, 168, 107966. https://doi.org/10.1016/j.neuropharm.2020.107966

Patsalos, P. N., Berry, D. J., Bourgeois, B. F., Cloyd, J. C., Glauser, T. A., Johannessen, S. I., Leppik, I. E., Tomson, T., & Perucca, E. (2008). Antiepileptic drugs—Best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia, 49(7), 1239–1276. https://doi.org/10.1111/j.1528-1167.2008.01561.x

National Institute of Diabetes and Digestive and Kidney Diseases. (2018, February 19). LiverTox: Clinical and Research Information on Drug-Induced Liver Injury – Ethosuximide. https://www.ncbi.nlm.nih.gov/books/NBK548146/

Mahmoud, S. H., Zhou, X. Y., & Ahmed, S. N. (2020). Managing the patient with epilepsy and renal impairment. Seizure, 76, 143–152. https://doi.org/10.1016/j.seizure.2020.01.005

Kuhnz, W., Koch, S., Jakob, S., Hartmann, A., Helge, H., & Nau, H. (1984). Ethosuximide in epileptic women during pregnancy and lactation period: Placental transfer, serum concentrations in nursed infants and clinical status. British Journal of Clinical Pharmacology, 18(5), 671–677. https://doi.org/10.1111/j.1365-2125.1984.tb02519.x

Pack, A. M., Oskoui, M., Williams Roberson, S., Donley, D. K., French, J., Gerard, E. E., Gloss, D., Miller, W. R., Munger Clary, H. M., Osmundson, S. S., McFadden, B., Parratt, K., Pennell, P. B., Saade, G., Smith, D. B., Sullivan, K., Thomas, S. V., Tomson, T., Dolan O'Brien, M., ... Keezer, M. R. (2024). Teratogenesis, perinatal, and neurodevelopmental outcomes after in utero exposure to antiseizure medication: Practice guideline from the AAN, AES, and SMFM. Neurology, 102(11), e209279. https://doi.org/10.1212/WNL.0000000000209279

National Institute of Child Health and Human Development. (2024, August 15). Drugs and Lactation Database (LactMed®) – Ethosuximide. https://www.ncbi.nlm.nih.gov/books/NBK501922/

Kanner, A. M., Ashman, E., Gloss, D., Harden, C., Bourgeois, B., Bautista, J. F., Abou-Khalil, B., Burakgazi-Dalkilic, E., Llanas Park, E., Stern, J., Hirtz, D., Nespeca, M., Gidal, B., Faught, E., & French, J. (2018). Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology, 91(2), 74–81. https://doi.org/10.1212/WNL.0000000000005755


Refbacks

  • There are currently no refbacks.